This quarter's most recent list of pending trials with general time frames to expected activation. Q1 2026Past reportsQ4 2025Q3 2025Q2 2025Q1 2025Q4 2024The planned and recently activated trials lists below is the most up to date and is dynamically generated from our database. Planned trials ALC11 Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy ALC9 Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE) BI4 Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC) BR39 LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial EN12 RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features HN14 Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC MA42 No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta) MD1 Combination Therapy with Luspatercept in Lower Risk Myelodysplasia: A Tier 1 myeloMATCH Substudy More >> ME18 Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3) SR8 NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR) Recently activated ALC10 Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial More >> CE10 VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma More >> LYC2 Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT) More >> PAC5 Lanreotide for the Prevention of Postoperative Pancreatic Fistula More >> SC30 Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT More >> SC31 Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO) More >> SC32S Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials More >>
